时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Arthritis, particularly rheumatoid arthritis (RA) and osteoarthritis (OA), is a multifactorial musculoskeletal disorder characterized by chronic inflammation, oxidative stress, immune dysregulation, mitochondrial dysfunction, extracellular…
方法
Although conventional therapies, including disease-modifying antirheumatic drugs, biologics and JAK inhibitors, have improved disease management, their long-term use is frequently associated with adverse effects, therapeutic resistance and…
核心结论
Although conventional therapies, including disease-modifying antirheumatic drugs, biologics and JAK inhibitors, have improved disease management, their long-term use is frequently associated with adverse effects, therapeutic resistance and incomplete…
局限
（原文未给出可直接抽取的对应表述）
对本项目的价值
临床前机制证据，需评估物种外推与剂量可行性：线粒体是衰老干预的共同下游效应器，可用于跨器官效应的统一读数。 ｜ 价值分 1.2/5（★☆☆☆☆）
全文来源
未取到全文 → 本卡为摘要级解读，未核验全文
原文题录
- 英文标题：Capsanthin at the crossroads of arthritis: from molecular mechanisms to therapeutic avenues.
- 期刊与标识：Inflammopharmacology · PMID 42955510 · DOI 10.1007/s10787-026-02437-6
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。